MedTrace Logo

GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT02321592 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-11-13

No results posted yet for this study

Summary

The study is designed

* to demonstrate efficacy of AFM13 with an optimized treatment schedule
* to decide whether AFM13 warrants further investigation in a phase III clinical trial

Conditions

Interventions

DRUG

AFM13

Sponsors & Collaborators

  • Affimed GmbH

    collaborator INDUSTRY

  • The Leukemia and Lymphoma Society

    collaborator OTHER

  • University of Cologne

    lead OTHER

Principal Investigators

  • Andreas Engert, Prof. · University Hospital of Cologne

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2019-11-30
Completion
2020-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02321592 on ClinicalTrials.gov